BioPharmX Reveals Positive Topline Phase 2a Clinical Trial Results For BPX-01

BioPharmX Corporation BPMX disclosed the topline results from its Phase 2a safety study of BPX-01, which is a unique topical gel formulation of minocycline. According to the company, results from the first human study of BPX-01 demonstrated the product reported no cutaneous toxicity and that there were no adverse effects. The study also found no detectable levels of minocycline in the patients' bloodstreams.

BioPharmX president and co-founder, Anja Krammer, said, "The findings confirm the data from preclinical studies of BPX-01 and reaffirm our belief that BPX-01 has the potential to revolutionize the way dermatologists treat acne with safer, more effective topical therapy."

He added, "These positive Phase 2a results allow us to proceed with next phase clinical studies with BPX-01 and we are optimistic that the planned Phase 2b study will further confirm the value of this product."

The company indicated that while all the Phase 2a results were positive, the finding that stood out most was the absence of detectable minocycline in the plasma of subjects getting BPX-01. The company added that when it was taken orally, the amount of minocycline found in the bloodstream is typically thousands of ng/ml that are often linked with significant systemic toxicity causing undesirable side effects.

At time of writing, the stock surged 27 percent on Wednesday.